How Xenon Works: Neuro and Cardioprotection Mechanisms

Detalhes bibliográficos
Autor(a) principal: Morais, Ricardo
Data de Publicação: 2014
Outros Autores: Andrade, Luísa, Lourenço, André, Tavares, Jorge
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/4782
Resumo: Introduction: The Xenon, a noble gas, has anesthetics properties, associated with remarkable hemodynamic stability as well as cardioprotective, neuroprotective proprieties. Its physicochemical characteristics give him a quick induction and emergence of anesthesia, being free of deleterious effects in all organs and showing no teratogenicity. Such properties have led to a growing interest in improving the knowledge about this noble gas, in order to assess the mechanisms of neuro and cardioprotection induced and to assess the clinical indications for its use.Material and Methods: Qualitative review of clinical trials on anesthesia with xenon. Studies were identified from MEDLINE and by hand-searching, using the following keywords: xenon, xenon anestesia, xenon neuroprotection, xenon cradioprotection.Results: After several studies, including two randomized multicenter controlled trials, the use of xenon as an anesthetic in patients ASA I-II was approved in March 2007. However his use in clinical practice has been strongly limited by it´s high price. It seems unlikely that the advantages it offers in relation to other anesthetics justify it´s use in patients ASA I-II. Although, xenon may be a valuable asset in the reduction of co-morbilities and mortality in anesthesia of patients ASA III-IV, unfortunately, there are no large randomized control studies to prove it.Discussion: Unfortunately, there are still no randomized or multicentric studies showing a favourable cost-benefit profile of xenon in ASA III-IV patients vs. other anaesthetics.Conclusion: The usefulness of xenon in Anesthesiology requires more studies to be defined.
id RCAP_29dfbf3e273c0af6a538d4fd4b28f13e
oai_identifier_str oai:ojs.www.actamedicaportuguesa.com:article/4782
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling How Xenon Works: Neuro and Cardioprotection MechanismsComo Funciona o Xénon: Mecanismos de Neuro e CardioprotecçãoIntroduction: The Xenon, a noble gas, has anesthetics properties, associated with remarkable hemodynamic stability as well as cardioprotective, neuroprotective proprieties. Its physicochemical characteristics give him a quick induction and emergence of anesthesia, being free of deleterious effects in all organs and showing no teratogenicity. Such properties have led to a growing interest in improving the knowledge about this noble gas, in order to assess the mechanisms of neuro and cardioprotection induced and to assess the clinical indications for its use.Material and Methods: Qualitative review of clinical trials on anesthesia with xenon. Studies were identified from MEDLINE and by hand-searching, using the following keywords: xenon, xenon anestesia, xenon neuroprotection, xenon cradioprotection.Results: After several studies, including two randomized multicenter controlled trials, the use of xenon as an anesthetic in patients ASA I-II was approved in March 2007. However his use in clinical practice has been strongly limited by it´s high price. It seems unlikely that the advantages it offers in relation to other anesthetics justify it´s use in patients ASA I-II. Although, xenon may be a valuable asset in the reduction of co-morbilities and mortality in anesthesia of patients ASA III-IV, unfortunately, there are no large randomized control studies to prove it.Discussion: Unfortunately, there are still no randomized or multicentric studies showing a favourable cost-benefit profile of xenon in ASA III-IV patients vs. other anaesthetics.Conclusion: The usefulness of xenon in Anesthesiology requires more studies to be defined.Introdução: O xénon, um gás nobre, possui qualidades anestésicas, associadas a uma notável estabilidade hemodinâmica assim como propriedades cardioprotectoras e neuroprotectoras. As suas características físico-químicas conferem-lhe uma rápida indução e emergência anestésica, estando livre de efeitos deletérios importantes nos diversos orgãos e não apresentando teratogenicidade; o que suscitou um recente recrudescimento no interesse de aprofundar o conhecimento sobre este gás nobre, afim de compreender osseus mecanismos de acção e determinar as várias indicações que possui para a prática clínica.Material e Métodos: Revisão da literatura dos artigos considerados relevantes sobre o tema, com recurso à pesquisa de artigos indexados na Medline, com as palavras-chaves: xénon, xénon anestesia, xénon neuroproteção, xénon cardioproteção.Resultados: A aprovação do uso do xénon em doentes ASA I-II, ocorreu em Março 2007, após a realização de dois ensaios clínicos aleatorizados multicêntricos. No entanto, o seu uso na prática clínica, tem sido limitado pelo seu preço elevado. Parece pouco provável que as vantagens que oferece em relação aos restantes anestésicos justifique o seu uso em doentes ASA I-II. No entanto, poderá ser uma preciosa ajuda para a redução das co-morbilidades e mortalidade na anestesia de doentes ASA III-IV. As suas propriedades neuro e cardio-protectoras, são também alvo de intensa investigação, com resultados promissores.Discussão: Infelizmente, ainda não existem estudos de aleatorizados e multicêntricos que comprovem um perfil favorável do custobenefício do xénon em doentes ASA III-IV, em relação aos demais anestésicos.Conclusão: O lugar do xénon na Anestesiologia ainda se encontra por definir.Ordem dos Médicos2014-04-30info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/4782oai:ojs.www.actamedicaportuguesa.com:article/4782Acta Médica Portuguesa; Vol. 27 No. 2 (2014): March-April; 259-265Acta Médica Portuguesa; Vol. 27 N.º 2 (2014): Março-Abril; 259-2651646-07580870-399Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/4782https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/4782/3863Morais, RicardoAndrade, LuísaLourenço, AndréTavares, Jorgeinfo:eu-repo/semantics/openAccess2022-12-20T11:03:59Zoai:ojs.www.actamedicaportuguesa.com:article/4782Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:18:58.411114Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv How Xenon Works: Neuro and Cardioprotection Mechanisms
Como Funciona o Xénon: Mecanismos de Neuro e Cardioprotecção
title How Xenon Works: Neuro and Cardioprotection Mechanisms
spellingShingle How Xenon Works: Neuro and Cardioprotection Mechanisms
Morais, Ricardo
title_short How Xenon Works: Neuro and Cardioprotection Mechanisms
title_full How Xenon Works: Neuro and Cardioprotection Mechanisms
title_fullStr How Xenon Works: Neuro and Cardioprotection Mechanisms
title_full_unstemmed How Xenon Works: Neuro and Cardioprotection Mechanisms
title_sort How Xenon Works: Neuro and Cardioprotection Mechanisms
author Morais, Ricardo
author_facet Morais, Ricardo
Andrade, Luísa
Lourenço, André
Tavares, Jorge
author_role author
author2 Andrade, Luísa
Lourenço, André
Tavares, Jorge
author2_role author
author
author
dc.contributor.author.fl_str_mv Morais, Ricardo
Andrade, Luísa
Lourenço, André
Tavares, Jorge
description Introduction: The Xenon, a noble gas, has anesthetics properties, associated with remarkable hemodynamic stability as well as cardioprotective, neuroprotective proprieties. Its physicochemical characteristics give him a quick induction and emergence of anesthesia, being free of deleterious effects in all organs and showing no teratogenicity. Such properties have led to a growing interest in improving the knowledge about this noble gas, in order to assess the mechanisms of neuro and cardioprotection induced and to assess the clinical indications for its use.Material and Methods: Qualitative review of clinical trials on anesthesia with xenon. Studies were identified from MEDLINE and by hand-searching, using the following keywords: xenon, xenon anestesia, xenon neuroprotection, xenon cradioprotection.Results: After several studies, including two randomized multicenter controlled trials, the use of xenon as an anesthetic in patients ASA I-II was approved in March 2007. However his use in clinical practice has been strongly limited by it´s high price. It seems unlikely that the advantages it offers in relation to other anesthetics justify it´s use in patients ASA I-II. Although, xenon may be a valuable asset in the reduction of co-morbilities and mortality in anesthesia of patients ASA III-IV, unfortunately, there are no large randomized control studies to prove it.Discussion: Unfortunately, there are still no randomized or multicentric studies showing a favourable cost-benefit profile of xenon in ASA III-IV patients vs. other anaesthetics.Conclusion: The usefulness of xenon in Anesthesiology requires more studies to be defined.
publishDate 2014
dc.date.none.fl_str_mv 2014-04-30
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/4782
oai:ojs.www.actamedicaportuguesa.com:article/4782
url https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/4782
identifier_str_mv oai:ojs.www.actamedicaportuguesa.com:article/4782
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/4782
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/4782/3863
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Ordem dos Médicos
publisher.none.fl_str_mv Ordem dos Médicos
dc.source.none.fl_str_mv Acta Médica Portuguesa; Vol. 27 No. 2 (2014): March-April; 259-265
Acta Médica Portuguesa; Vol. 27 N.º 2 (2014): Março-Abril; 259-265
1646-0758
0870-399X
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799130640605511680